DRAXIS HEALTH INC

verwässert mit neuen Aktien. Nun 120 Mio Shares Outstanding. Schade irgendwie, aber Kurse von 1,5 USD sind sicherlich trotzdem langfristig drin, wenn man mal mit Calypte Bio vergleicht, die haben glaube ich 133 Mio Shares? Müßte ich nochmal nachschauen dann. Das ist aber der Grund, warum sie Fallen, mehr Aktien am Markt!

Hatte mich shcon gewundert, wie ein Pennystock zu so einem Medikament kommt! Da ich auch in Draxis investiert bin, kam die Verwechslung!!

Centrex Announces Milestone, Trades Up 32.84% on 12X Volume (Printer friendly version) Feb 10, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Centrex (OTCBB: CNEX) traded up 32.84% to close at $0.089 Monday on volume of 11,446,690, or 12 times its average volume of $991,016, following an announcement that Micronics, Inc. has advanced the development of an assay that contains Centrex's single molecule nucleic acid detection technology for application in a laboratory-on-a-card format. Micronics reported to Centrex that it has achieved the initial milestone which permits lysis and binding reactions in the lab card format. The company said SMD technology, in combination with an easy-to-operate lab card device and integrated reader, is expected to be responsive to the need for rapid, user friendly and cost effective solutions for point-of-use analyses of a variety of bacterial and viral organisms. Centrex's SMD technology was exclusively licensed from Los Alamos National Laboratories, and offers important advantages over existing DNA and RNA detection methods as well as culture-based test methods. SMD technology eliminates the need for amplification of the target DNA by recognizing the unique DNA or RNA fingerprint of the target organism. This reduces the possibility of false positive and negative test results - common concerns frequently identified with other test procedures. As a next step in the development process, Micronics is expected to integrate the lysing/binding reactions together with SMD using a biological stimulant, the spores of the bacteria Bacillus globigii. Bacillus globigii prepared in this manner may be used safely to simulate Bacillus anthracis (anthrax) spores in the DNA extraction and binding experiments. Centrex was enrolled in Investrend Research's unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following, but its coverage is presently suspended due to the company's failure to provide access to the analyst as required by the issuer standards of the Association for Investment Management and Research. The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at http://www.investrendresearch.com Investrend Research is a member of the FIRST Research Consortium at http://www.firstresearchconsortium.com, and participates in the organization's standards development panel for independent research providers. The "Standards for Independent Research Providers" may be viewed at http://www.investrend.com/Admin/Topics/Articles/Resources/871_1060440861.doc The Dow Jones (NYSE: DJ) Newswires has stated that independent research has been growing in credibility over the past 18 months, specifically citing Investrend Research, and the New York Times (NYSE: NYT) has reported a survey by Charles Schwab & Co. (NYSE: SCH) reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential." Enrollment fees for Institutional coverage were $23,400, and the fees were paid by the company. There is an open invoice for $13,700 remaining on account. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms. Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company. For up-to-the-minute news, features and links click on http://www.financialwire.net FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268 URL: http://www.financialwire.net